Literature DB >> 16221664

Isolation of monomeric human V(H)s by a phage selection.

Rebecca To1, Tomoko Hirama, Mehdi Arbabi-Ghahroudi, Roger MacKenzie, Ping Wang, Ping Xu, Feng Ni, Jamshid Tanha.   

Abstract

Human V(H) domains are promising molecules in applications involving antibodies, in particular, immunotherapy because of their human origin. However, they are, in general, prone to aggregation. Therefore, various strategies have been employed to acquire monomeric human V(H)s. We had previously discovered that filamentous phages displaying engineered monomeric V(H) domains gave rise to significantly larger plaques on bacterial lawns than phages displaying wild type V(H)s with aggregation tendencies. Using plaque size as the selection criterion and a phage-displayed naïve human V(H) library we identified 15 V(H)s that were monomeric. Additionally, the V(H)s demonstrated good expression yields, good refolding properties following thermal denaturation, resistance to aggregation during long incubation at 37 degrees C, and to trypsin at 37 degrees C. These 15 V(H)s should serve as good scaffolds for developing immunotherapeutics, and the selection method employed here should have general utility for isolating proteins with desirable biophysical properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221664     DOI: 10.1074/jbc.M509900200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Evaluation of a noncanonical Cys40-Cys55 disulfide linkage for stabilization of single-domain antibodies.

Authors:  Dae Young Kim; Hiba Kandalaft; Greg Hussack; Shalini Raphael; Wen Ding; John F Kelly; Kevin A Henry; Jamshid Tanha
Journal:  Protein Sci       Date:  2019-03-14       Impact factor: 6.725

2.  Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.

Authors:  Greg Hussack; Mehdi Arbabi-Ghahroudi; Henk van Faassen; J Glenn Songer; Kenneth K-S Ng; Roger MacKenzie; Jamshid Tanha
Journal:  J Biol Chem       Date:  2011-01-07       Impact factor: 5.157

Review 3.  Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.

Authors:  Greg Hussack; Jamshid Tanha
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

Review 4.  Biotechnological applications of recombinant single-domain antibody fragments.

Authors:  Ario de Marco
Journal:  Microb Cell Fact       Date:  2011-06-09       Impact factor: 5.328

5.  Engineered single-domain antibodies with high protease resistance and thermal stability.

Authors:  Greg Hussack; Tomoko Hirama; Wen Ding; Roger Mackenzie; Jamshid Tanha
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

6.  Crystal structure of a human single domain antibody dimer formed through V(H)-V(H) non-covalent interactions.

Authors:  Toya Nath Baral; Shi-Yu Chao; Shenghua Li; Jamshid Tanha; Mehdi Arbabi-Ghahroudi; Jianbing Zhang; Shuying Wang
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

7.  Multivalent anchoring and oriented display of single-domain antibodies on cellulose.

Authors:  Greg Hussack; Yan Luo; Linda Veldhuis; J Christopher Hall; Jamshid Tanha; Roger Mackenzie
Journal:  Sensors (Basel)       Date:  2009-07-07       Impact factor: 3.576

Review 8.  An update on antibody-based immunotherapies for Clostridium difficile infection.

Authors:  Greg Hussack; Jamshid Tanha
Journal:  Clin Exp Gastroenterol       Date:  2016-08-01

9.  Antibody light chain variable domains and their biophysically improved versions for human immunotherapy.

Authors:  Dae Young Kim; Rebecca To; Hiba Kandalaft; Wen Ding; Henk van Faassen; Yan Luo; Joseph D Schrag; Nadereh St-Amant; Mary Hefford; Tomoko Hirama; John F Kelly; Roger MacKenzie; Jamshid Tanha
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

10.  Directed evolution of human heavy chain variable domain (VH) using in vivo protein fitness filter.

Authors:  Dong-Sik Kim; Hyung-Nam Song; Hyo Jung Nam; Sung-Geun Kim; Young-Seoub Park; Jae-Chan Park; Eui-Jeon Woo; Hyung-Kwon Lim
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.